Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

Health Care

General

Genenta Science Has Dosed First Of Three Patients In Cohort 8 (Temferon At 4X10^6/Kg), The Last Cohort Of Phase 1 Dose-ranging Part Of Phase 1/2 Trial In Newly Diagnosed uMGMT Glioblastoma Multiforme Patients; Top Line Data Expected By End Of 2Q24 - Genenta Science (NASDAQ:GNTA)

Benzinga Newsdesk

Genenta Science

GNTA

Genenta Science Has Dosed First Of Three Patients In Cohort 8 (Temferon At 4X10^6/Kg), The Last Cohort Of Phase 1 Dose-ranging Part Of Phase 1/2 Trial In Newly Diagnosed uMGMT Glioblastoma Multiforme Patients; Top Line Data Expected By End Of 2Q24

Comments